Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amar Patel

Pain Medicine Thornton, CO Medical Doctor

NPI 1922310119 CMS profile 1016133

9351 Grant St Ste 490, Thornton, CO 80229

Open in the dashboard

General payments

$46,668

793 records reported · program years 2019–2025

Research payments

$230

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$99,688 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Amar Patel of Thornton, CO is reported in the CMS Open Payments database as having received $46,668 across 793 general payments and $230 in research payments paid to them. Separately, studies naming them as principal investigator received $99,688 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,376 88
2024 General $7,235 131
2023 General $5,613 114
2022 General $11,017 125
2021 General $9,433 110
2021 Research $230 1
2020 General $5,945 92
2019 General $4,048 133

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amar Patel
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Amar Patel were reported at $3,376. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Amar Patel Pain Medicine median Middle half National median
2019 $4,048 $409 $115–$1,311 $163
2020 $5,945 $214 $66–$666 $114
2021 $9,433 $299 $84–$899 $132
2022 $11,017 $335 $103–$1,149 $149
2023 $5,613 $376 $114–$1,228 $160
2024 $7,235 $387 $115–$1,173 $164
2025 $3,376 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $21,938 206 payments
  2. Medtronic USA, Inc. $6,472 89 payments
  3. Saluda Medical Americas, Inc. $3,188 32 payments
  4. AbbVie, Inc. $2,427 120 payments
  5. Painteq LLC $1,812 14 payments
  6. SI-BONE, Inc. $1,503 21 payments
  7. Abbott Laboratories $1,284 37 payments
  8. MML US, Inc. $1,248 7 payments
  9. Relievant Medsystems, Inc. $908 11 payments
  10. Scilex Pharmaceuticals Inc. $598 33 payments
  11. Other $5,288 223 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $24,499 733 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,375 5 payments
  3. Travel and Lodging $9,743 50 payments
  4. Consulting Fee $1,050 1 payment
  5. Education $1,000 4 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $4,762 88 payments
  2. Evoke $3,188 32 payments
  3. INTELLIS Spinal Cord Neurostimulation $2,565 31 payments
  4. SYNCHROMEDII $2,409 32 payments
  5. VANTA ADAPTIVESTIM $2,011 10 payments
  6. PAINTEQ $1,812 14 payments
  7. INTELLIS Spinal Cord Neurostimulation $1,434 20 payments
  8. BOTOX $1,288 63 payments
  9. ReActiv8 $1,248 7 payments
  10. IFUSE IMPLANT SYSTEM $1,085 6 payments
  11. Other $16,446 537 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $230 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

83

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$3,795

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

59%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 13 $2,882
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 20 $320
Baclofen Generic 11 $207
Gabapentin Generic 11 $156
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 16 $128
Oxycodone Hcl Generic 12 $101

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$271,083

Of which drugs: $111,048

Medicare patients

213

Average age 68

Services billed

29,165

128 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 65%
Depression 37%
Diabetes 31%
Ischemic heart disease 28%
Chronic kidney disease 25%
Osteoporosis 20%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 14 11,150 $53,494
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg J2274 Office 15 1,251 $11,161
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 115 799 $4,363
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 14 552 $152
Injection, midazolam hydrochloride, per 1 mg J2250 Office 45 262 $27
Injection, fentanyl citrate, 0.1 mg J3010 Office 15 19 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
$407 — 11,150
QULIPTA
$264 — —
Prialt
$134 — —
Qutenza
$99 — —
UBRELVY
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

794 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record